BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Press Releases

  IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

  August 31, 2026

   · 

  8 min read
• Press Releases

  BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

  August 31, 2026

   · 

  8 min read
• 

  Approvals

  Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity

  The approval of rusfertide—now to be branded Mimrylo—for polycythemia vera marks a key win for Takeda, which now has crossed the FDA finish line for two of three critical product launches slated for the coming year.

  August 31, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split

  Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.

  August 31, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

  August 31, 2026

   · 

  5 min read
• Press Releases

  Novo Nordisk A/S - share repurchase programme - August 31, 2026

  August 31, 2026

   · 

  2 min read
• Press Releases

  Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

  August 31, 2026

   · 

  6 min read
• Press Releases

  Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

  August 31, 2026

   · 

  5 min read
• Press Releases

  New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

  August 31, 2026

   · 

  22 min read
• Press Releases

  Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity

  August 31, 2026

   · 

  3 min read